Evaluation of the functional activity and specificity of the hSLPI gene promoter
- Authors: Dudkina E.V.1, Kosnyrev A.S.1, Ulyanova V.V.1, Nadyrova A.I.1, Morozova P.S.1, Kupriyanova E.A.1, Ilinskaya O.N.1
-
Affiliations:
- Kazan Federal University, Kazan
- Section: Original Study Articles
- Published: 26.08.2024
- URL: https://rjonco.com/1028-9984/article/view/629570
- DOI: https://doi.org/10.17816/onco629570
- ID: 629570
Cite item
Abstract
BACKGROUND: One of the main problems of modern oncotherapy is the lack of selectivity of the antitumor drugs, leading to their systemic toxicity on the body. Targeted expression of therapeutic genes represents a new approach in cancer gene therapy. One of the ways to achieve the selectivity of action of the therapeutic genes towards tumor cells is the use of promoters that are active only in tumor cells, but not in normal cells.
AIM: To evaluate the functional activity and specificity of the promoter of the human secretory leukocyte protease inhibitor hSLPI.
MATERIALS AND METHODS: The promoter of the hSLPI gene was cloned into the promotorless vector pTurboGFP-PRL. The functional activity and specificity of the promoter were assessed by the expression of the mRNA of the TurboGFP reporter gene and the intensity of its luminescence in A549, MCF-7, HeLa tumor cells and WI-38 normal cells using real-time polymerase chain reaction with reverse transcription and fluorescence analysis, respectively.
RESULTS: Despite the literature data, the promoter of the hSLPIa gene demonstrated high transcriptional activity only against HeLa cervical cancer tumor cells. At the same time, in the cells of lung adenocarcinoma A549 and breast cancer MCF-7, as in normal WI-38 cells, a reduced level of promoter activity was observed.
CONCLUSION: The data obtained confirm the need for a preliminary assessment of the functional activity of tumor-specific promoters in relation to tumor and normal cells.
Keywords
Full Text
![Restricted Access](https://rjonco.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
Elena V. Dudkina
Kazan Federal University, Kazan
Email: ElVDudkina@kpfu.ru
ORCID iD: 0000-0002-2817-1384
SPIN-code: 5874-7417
Cand. Sci. (Biol.), Assistant Professor
Russian FederationAlexander S. Kosnyrev
Kazan Federal University, Kazan
Email: s_kosnyrev@mail.ru
ORCID iD: 0009-0008-4341-5181
SPIN-code: 8593-7837
Russian Federation
Vera V. Ulyanova
Kazan Federal University, Kazan
Email: Vera.Uljanova@kpfu.ru
ORCID iD: 0000-0003-1768-3314
SPIN-code: 8479-4593
Cand. Sci. (Biology), Assistant Professor
Russian FederationAlsu I. Nadyrova
Kazan Federal University, Kazan
Email: alsu.nadyrova@yandex.ru
ORCID iD: 0000-0002-1312-0605
SPIN-code: 9618-7816
Russian Federation
Polina S. Morozova
Kazan Federal University, Kazan
Email: polinam0r0zz@ya.ru
ORCID iD: 0009-0006-7205-5774
Russian Federation
Elena A. Kupriyanova
Kazan Federal University, Kazan
Email: elena.a.kupriyanova@gmail.com
ORCID iD: 0000-0002-9185-4217
SPIN-code: 9456-5596
Russian Federation
Olga N. Ilinskaya
Kazan Federal University, Kazan
Author for correspondence.
Email: Olga.Ilinskaya@kpfu.ru
ORCID iD: 0000-0001-6936-2032
SPIN-code: 7972-5807
Russian Federation
References
- Sasaki H, Endo K, Okuda K, et al. Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. Journal of cancer research and clinical oncology. 2008;134:569–577. doi: 10.1007/s00432-007-0320-z
- Montaño-Samaniego M, Bravo-Estupiñan DM, Méndez-Guerrero O, Alarcón-Hernández E, Ibáñez-Hernández M. Strategies for targeting gene therapy in cancer cells with tumor-specific promoters. Frontiers in oncology. 2020;10:609380. doi: 605380.10.3389/fonc.2020.605380
- Aiuti A, Roncarolo MG, Naldini L. Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products. EMBO Mol Med. 2017;9(6):737–740. doi: 10.15252/emmm.201707573
- Yan M, Chen J, Jiang H, et al. Effective inhibition of cancer cells by recombinant adenovirus expressing EGFR-targeting artificial microRNA and reversed-caspase-3. PLoS One. 2020;15(8):e0237098. doi: 10.1371/journal.pone.0237098
- Ginn SL, Amaya AK, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2017: An update. J Gene Med. 2018;20(5):1–16. doi: 10.1002/jgm.3015
- Rama Ballesteros A, Hernández R, Perazzoli G, et al. Specific driving of the suicide E gene by the CEA promoter enhances the effects of paclitaxel in lung cancer. Cancer Gene Ther. 2020;27:657–668. doi: 10.1038/s41417-019-0137-3
- Chen C, Yue D, Lei L, et al. Promoter-operating targeted expression of gene therapy in cancer: current stage and prospect. Molecular Therapy-Nucleic Acids. 2018;11:508–514. doi: 10.1016/j.omtn.2018.04.003
- Wang Y, Xu HX, Lu MD, Tang Q. Expression of thymidine kinase mediated by a novel non-viral delivery system under the control of vascular endothelial growth factor receptor 2 promoter selectively kills human umbilical vein endothelial cells. World Journal of Gastroenterology: WJG. 2008;14(2):224. doi: 10.3748/wjg.14.224
- Naoum GE, Zhu ZB, Buchsbaum DJ, Curiel DT, Arafat WO. Surviving a radiogenetic promoter for glioblastoma viral gene therapy independently from CArG motifs. Clinical and Translational Medicine. 2017;6:1–11. doi: 10.1186/s40169-017-0140-y
- Suhail Y, Cain MP, Vanaja K, et al. Systems biology of cancer metastasis. Cell systems. 2019;9(2):109–127. doi: 10.1016/j.cels.2019.07.003
- Sambrook J, Russell DW. Molecular Cloning: A Laboratory Manual. 3d ed. Cold Spring Harbor: Cold Spring Harbor Lab. Press; 2001.
- Chen J, Yang B, Zhang S, et al. Antitumor potential of SLPI promoter controlled recombinant caspase-3 expression in laryngeal carcinoma. Cancer Gene Ther. 2012;19(5):328–335. doi: 10.1038/cgt.2012.5.
- Sahdev S, Saini S, Tiwari P, Saxena S, Saini KS. Amplification of GC-rich genes by following a combination strategy of primer design, enhancers and modified PCR cycle conditions. Molecular and cellular probes. 2007;21(4):303–307. doi: 10.1016/j.mcp.2007.03.004
- Shuhong H, Xiaoyuan D, Yang S, et al. Targeted gene therapy of the HSV-TK/hIL-12 fusion gene controlled by the hSLPI gene promoter of human non-small cell lung cancer in vitro. Oncology Letters. 2018;15(5):6503–6512. doi: 10.3892/ol.2018.8148
- Robertson MW, Wang M, Siegal GP, et al. Use of a tissue-specific promoter for targeted expression of the herpes simplex virus thymidine kinase gene in cervical carcinoma cells. Cancer Gene Ther. 1998;5:331–336.
- Zuo J, Zhang C, Ren C, et al. Secretory leukocyte protease inhibitor is a proliferation and survival factor for pancreatic cancer cells. Clin Transl Oncol. 2015;17(4):314–321. doi: 10.1007/s12094-014-1232-4
- Barker SD, Coolidge CJ, Kanerva A, et al. The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy. The Journal of Gene Medicine. 2003;5(4):300–310. doi: 10.1002/jgm.341
- Maemondo M, Saijo Y, Narumi K, et al. Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer. Cancer research. 2004;64(13):4611–4620. doi: 10.1158/0008-5472.CAN-03-2549
Supplementary files
![](/img/style/loading.gif)